Adverse Events Following Immunization: Mechanisms, Clinical Manifestations, Surveillance, and Public Health Management-A Narrative Review

Abstract

Immunization is a cornerstone of global public health, preventing substantial morbidity and mortality worldwide. However, the long-term success of immunization programs depends not only on vaccine effectiveness but also on robust systems for monitoring and managing vaccine safety. Adverse Events Following Immunization (AEFIs), defined by the World Health Organization (WHO) as any untoward medical occurrence that follows immunization and does not necessarily have a causal relationship with vaccine use, remain an important challenge for vaccine safety surveillance and public confidence. This narrative review synthesizes evidence on the classification, biological and immunological mechanisms, clinical manifestations, surveillance, causality assessment, and public health management of AEFIs. Literature was identified through searches of PubMed/MEDLINE and Scopus, complemented by relevant grey literature from authoritative organizations, including WHO and the United States Centers for Disease Control and Prevention (CDC). The review considers evidence from both COVID-19 and non-COVID-19 vaccination programs, with emphasis on vaccine safety surveillance, pharmacovigilance, clinical assessment, and public health response. AEFIs were examined according to the WHO classification framework, comprising vaccine product–related, vaccine quality defect–related, immunization error–related, immunization anxiety–related, and coincidental events. Biological and immunological mechanisms range from expected innate inflammatory responses to rare immune-mediated and hypersensitivity reactions. Although most AEFIs are mild and self-limiting, rare serious events require timely recognition, investigation, and appropriate clinical management. Global vaccine safety monitoring capacity remains uneven, with substantial differences in reporting, surveillance infrastructure, diagnostic capacity, and health-system resources across settings. Strengthening pharmacovigilance, active and passive surveillance, healthcare worker training, causality assessment, and transparent risk communication is essential to ensure vaccine safety, sustain public confidence, and support the continued success of immunization programs worldwide.

Background

Vaccination represents one of the most successful public health interventions in history, preventing millions of deaths annually and substantially reducing the global burden of infectious diseases.¹ Despite these achievements, the effectiveness of immunization programs is intrinsically linked to public confidence in vaccine safety. Concerns regarding adverse events, whether substantiated or perceived, can significantly influence vaccine acceptance and coverage.² The World Health Organization defines an Adverse Event Following Immunization (AEFI) as “any untoward medical occurrence which follows immunization and which does not necessarily have a causal relationship with the usage of the vaccine.” This definition emphasizes the distinction between temporal association and causality, a critical concept in vaccine safety assessment.³ Vaccine safety monitoring is an important component of pharmacovigilance, which encompasses the detection, assessment, understanding, and prevention of adverse effects or other drug- and vaccine-related problems. Within immunization programs, pharmacovigilance provides the broader framework through which AEFI reports are collected, investigated, evaluated for causality, and used to detect potential safety signals.⁴ Effective vaccine pharmacovigilance therefore extends beyond identifying individual adverse events to include systematic surveillance, signal detection, epidemiological investigation, risk assessment, and communication of vaccine-safety information.^5,6 Despite the expansion of global vaccine-safety monitoring systems, substantial differences remain in the capacity of countries to detect, investigate, and report AEFIs. Surveillance performance is influenced by differences in health-system infrastructure, availability of trained personnel, laboratory and diagnostic capacity, reporting practices, regulatory systems, and access to reliable health information systems.⁷ These disparities are particularly important when interpreting evidence across income settings, because lower reporting rates may reflect limitations in surveillance capacity or underreporting rather than a genuinely lower frequency of adverse events.⁸ Historically, safety controversies such as those related to whole-cell pertussis vaccines or influenza vaccines have had measurable impacts on immunization uptake, reinforcing the need for transparent and scientifically grounded safety monitoring systems.⁹ This narrative review aims to synthesize existing literature on the classification, biological mechanisms, clinical manifestations, and public health management of AEFIs. By integrating clinical and policy perspectives, the review seeks to inform clinicians, public health practitioners, and policymakers navigating the complex and evolving landscape of vaccine safety.

Methodology

This narrative review was conducted to synthesize current evidence on adverse events following immunization (AEFIs), with particular emphasis on their classification, biological and immunological mechanisms, clinical manifestations, surveillance, causality assessment, and public health management. Literature searches were conducted in PubMed/MEDLINE and Scopus for publications available up to September 2026. The search strategy combined terms including “adverse events following immunization”, “AEFI surveillance”, “vaccine safety”, “pharmacovigilance”, “causality assessment”, and “vaccine adverse events.” In addition to peer-reviewed literature, grey literature from authoritative organizations, particularly the World Health Organization (WHO) and the United States Centers for Disease Control and Prevention (CDC), was reviewed to capture international vaccine-safety guidance and surveillance evidence. Priority was given to systematic reviews, meta-analyses, large observational studies, vaccine-safety surveillance studies, pharmacovigilance analyses, clinical studies of serious AEFIs, and international guidelines. Evidence from both COVID-19 and non-COVID-19 vaccination programs was considered to provide a broader perspective on AEFI surveillance and management. Studies and reports were selected based on their relevance to the objectives of the review rather than through a formal systematic-review screening and risk-of-bias process. The evidence was narratively synthesized according to five interconnected domains: (1) AEFI classification; (2) biological and immunological mechanisms; (3) clinical manifestations; (4) surveillance and causality assessment; and (5) public health management and policy implications. Given the narrative design, no quantitative meta-analysis was undertaken. The review therefore aims to provide an integrated clinical and public health interpretation of the available evidence rather than a pooled estimate of AEFI incidence or risk.

Classification of Adverse Events Following Immunization

AEFIs are heterogeneous in nature, and standardized classification is essential for surveillance, investigation, and response. The WHO classifies AEFIs according to their presumed cause, facilitating consistent reporting and causality assessment.¹⁰

Vaccine Product–Related Reactions

Vaccine product–related reactions arise from the inherent properties of the vaccine or its components, including antigens, adjuvants, preservatives, and stabilizers. Live attenuated vaccines may occasionally produce mild symptoms resembling the natural infection, while inactivated vaccines are more commonly associated with transient local or systemic inflammatory responses. These reactions are typically predictable and reflect expected immune activation.³

Vaccine Quality Defect–Related Reactions

Quality defect–related reactions result from issues in vaccine manufacturing, storage, or transportation that compromise vaccine integrity. Cold chain failures, contamination, or deviations in production standards may reduce potency or increase reactogenicity. Such events underscore the importance of rigorous quality assurance and regulatory oversight throughout the vaccine supply chain.¹¹

Immunization Error–Related Reactions

Immunization error related reactions are preventable events caused by inappropriate handling, preparation, or administration of vaccines. Examples include incorrect dosing, use of non-sterile equipment, or administration via an improper route. These reactions highlight the critical role of healthcare worker training and adherence to standardized immunization practices.^12,13

Immunization Anxiety Related Reactions

Immunization anxiety–related reactions are psychogenic responses associated with fear or stress related to vaccination rather than the vaccine itself. Manifestations include vasovagal syncope, hyperventilation, and, in some cases, mass psychogenic illness. These events are particularly relevant in school-based or mass vaccination settings.^14,15

Coincidental Events

Coincidental events are medical conditions that occur following vaccination by chance alone, without a causal relationship. Differentiating coincidental events from vaccine-related reactions is a central challenge in vaccine safety surveillance and a key function of structured causality assessment.¹⁶

AEFIs can be classified according to their underlying causes, including vaccine product-related reactions, vaccine quality defect-related reactions, immunization error-related reactions, immunization anxiety-related reactions, and coincidental events. The main categories of AEFIs, their definitions, and relevant examples are summarized in Table 1.

Table 1.

Classification, Examples, Detection Priorities, and Public Health Management of AEFIs

AEFI Category	Typical Examples	Key Detection/Investigation Focus	Public Health Response
Vaccine product-related	Fever, local inflammation, expected systemic reactions	Clinical assessment and known safety profile	Symptomatic management and communication
Vaccine quality defect-related	Reactions associated with compromised vaccine integrity	Cold-chain, manufacturing and batch investigation	Product investigation and regulatory action
Immunization error-related	Incorrect dose, route, preparation or administration	Review of vaccination procedures	Corrective training and system improvement
Immunization anxiety-related	Syncope, hyperventilation, stress-related symptoms	Clinical assessment and contextual investigation	Psychological support and appropriate communication
Coincidental	Medical condition occurring after vaccination without causal relationship	Differential diagnosis and background incidence	Appropriate clinical care and causality assessment

Biological and Immunological Mechanisms

Local adverse reactions such as pain, erythema, and swelling are primarily mediated by innate immune responses at the injection site. Activation of pattern recognition receptors and subsequent cytokine release contribute to inflammation, which may be enhanced by adjuvants designed to improve immunogenicity.¹⁷ Systemic symptoms such as fever, fatigue, and malaise reflect the activation of adaptive immune responses and cytokine-mediated signaling.¹⁸ In rare cases, hypersensitivity reactions may occur, including IgE-mediated anaphylaxis triggered by vaccine excipients such as gelatin or polyethylene glycol.¹⁹ The risk and nature of AEFIs are influenced by host-related factors, including age, sex, genetic predisposition, and underlying medical conditions. Understanding these factors is increasingly important in the context of personalized medicine and risk stratification.¹⁷

Clinical Manifestations of Aefi

The majority of AEFIs are mild, self-limiting, and resolve without intervention. Local reactions, including pain and redness at the injection site, are the most frequently reported.²⁰ Systemic reactions such as fever, headache, and myalgia are also common. The clinical spectrum of AEFIs varies according to vaccine type, recipient characteristics, and the underlying immunological response.²¹ Common reactions include local pain, erythema, and swelling, as well as systemic symptoms such as fever, headache, fatigue, and myalgia.²² Evidence from routine childhood immunization, influenza vaccination, and more recent COVID-19 vaccination programs demonstrates that most reported reactions are mild and self-limiting.²³ During the COVID-19 vaccination era, expanded surveillance generated substantial evidence concerning both common reactogenicity and rare serious events, including myocarditis following mRNA vaccines and thrombosis with thrombocytopenia syndrome following some adenovirus-vector vaccines.²⁴ These observations complement, rather than replace, evidence accumulated from established non-COVID-19 vaccination programs. Serious AEFIs are rare but clinically significant. Anaphylaxis is an acute, life-threatening hypersensitivity reaction that typically occurs within minutes of vaccination.⁸ Neurological events, such as febrile seizures, may occur infrequently following certain childhood vaccines, while Guillain–Barré syndrome has been associated with a very small increased risk following specific influenza vaccines.²⁵ Special considerations have emerged during the COVID-19 vaccination era, including thrombosis with thrombocytopenia syndrome linked to adenovirus-vector vaccines and myocarditis associated with mRNA vaccines.^26,27

Surveillance, Detection, and Causality Assessment

Effective pharmacovigilance underpins vaccine safety assurance. Passive surveillance systems, including national spontaneous reporting mechanisms, are essential for signal detection but are limited by underreporting and variable data quality. As of 2022, only 43% of countries met the WHO target for reporting serious AEFIs.²⁸ Active surveillance systems, such as the Vaccine Safety Datalink, utilize linked healthcare databases to enable near real-time monitoring and robust epidemiological analysis.²⁹ Causality assessment is a structured process used to determine whether a vaccine is likely responsible for an adverse event.¹⁶ The WHO causality assessment algorithm evaluates temporal relationships, biological plausibility, and alternative explanations. Application of this framework has demonstrated good inter-rater reliability among trained assessors.³⁰

Public Health Management and Policy Implications

Preparedness for managing severe AEFIs, particularly anaphylaxis, is essential at all vaccination sites. Equally important is transparent, timely, and empathetic risk communication to address public concerns and mitigate vaccine hesitancy.²⁸ Sustainable vaccine safety systems require ongoing investment in infrastructure, cold chain maintenance, and healthcare worker training. Strengthening reporting practices and fostering a culture of safety are critical components of effective immunization programs.³¹

Knowledge Gaps and Future Research Priorities

Despite substantial progress in vaccine safety monitoring, important knowledge gaps remain. First, AEFI surveillance capacity remains uneven across countries and health systems, limiting the comparability of safety data between settings.³² Underreporting, incomplete clinical information, inconsistent case definitions, and differences in diagnostic capacity may result in substantial variation in reported AEFI patterns.³³ Second, distinguishing vaccine-related events from coincidental medical conditions remains challenging, particularly when background rates of common diseases are high.³⁴ Strengthening epidemiological methods for signal detection and incorporating reliable background incidence data are therefore essential for improving causal interpretation.³⁵ Third, additional research is needed to better characterize host-related factors that may influence susceptibility to specific AEFIs, including age, sex, genetic factors, previous exposure, underlying conditions, and concomitant medications. Such research could support more refined approaches to risk stratification while avoiding inappropriate conclusions regarding individual vaccine safety.³³ Fourth, digital health technologies, electronic health records, active surveillance platforms, and automated signal-detection approaches offer opportunities for more timely identification of potential safety signals.³ However, their implementation requires appropriate data governance, interoperability, analytical capacity, and validation across diverse health-system settings.³⁶ Future research should therefore prioritize strengthening surveillance systems in under-resourced settings, improving the completeness and quality of AEFI reporting, establishing reliable background rates for clinically important events, evaluating novel signal-detection approaches, and developing standardized approaches for communicating uncertainty and causality to healthcare professionals and communities.

Conclusion

AEFIs are an important component of vaccine safety surveillance, although most are mild and not causally related to vaccination. Effective management requires timely detection, standardized investigation, causality assessment, appropriate clinical care, and transparent risk communication. Strengthening pharmacovigilance, surveillance capacity, healthcare worker training, and public engagement is essential to detect rare safety signals, maintain vaccine confidence, and sustain effective immunization programs worldwide.

Funding Statement

No funding was received for this work.

Data Sharing Statement

This manuscript is based on published literature and publicly available reports.

Ethics Approval and Consent to Participate

Ethical statement is not applicable.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors declare that they have no competing interests.